1. Home
  2. ATNM vs CXAI Comparison

ATNM vs CXAI Comparison

Compare ATNM & CXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$0.91

Market Cap

31.7M

Sector

Health Care

ML Signal

HOLD

Logo CXApp Inc.

CXAI

CXApp Inc.

HOLD

Current Price

$0.13

Market Cap

27.8M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNM
CXAI
Founded
2000
N/A
Country
United States
United States
Employees
N/A
35
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
31.7M
27.8M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ATNM
CXAI
Price
$0.91
$0.13
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.50
N/A
AVG Volume (30 Days)
118.1K
7.0M
Earning Date
05-06-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
14.17
N/A
EPS
N/A
N/A
Revenue
$90,000.00
N/A
Revenue This Year
N/A
$33.54
Revenue Next Year
N/A
$116.67
P/E Ratio
N/A
N/A
Revenue Growth
11.11
N/A
52 Week Low
$0.88
$0.13
52 Week High
$1.89
$1.15

Technical Indicators

Market Signals
Indicator
ATNM
CXAI
Relative Strength Index (RSI) 40.22 35.25
Support Level N/A N/A
Resistance Level $1.27 $0.20
Average True Range (ATR) 0.05 0.01
MACD -0.00 -0.00
Stochastic Oscillator 21.59 10.68

Price Performance

Historical Comparison
ATNM
CXAI

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

About CXAI CXApp Inc.

CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. Its cloud-based, mobile-first platform integrates artificial intelligence, automation, and real-time analytics to streamline workplace interactions across people, spaces, and technology. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, Agentic AI Capabilities, and CXAI-VU. The company generates the majority of its revenue from Licenses.

Share on Social Networks: